The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer
CLINICAL CANCER RESEARCH(2023)
摘要
Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698
更多查看译文
关键词
ovarian cancer,genomic biomarkers,immunotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要